Increase of hemoglobin A2 in human immunodeficiency virus-1-infected patients treated with zidovudine
| Autor: | Emil Toma, Line St‐Pierre, Marc Monte, Marc Dumont, Raymond Beaulieu, Jean-Pierre Routy |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Sexually transmitted disease medicine.medical_specialty medicine.medical_treatment Gastroenterology Asymptomatic Zidovudine Hemoglobin A2 Immunopathology Internal medicine Humans Medicine Neoplasm Staging Acquired Immunodeficiency Syndrome Chemotherapy business.industry Retrospective cohort study Hematology Middle Aged Blood Cell Count Immunology HIV-1 Female Viral disease medicine.symptom business medicine.drug |
| Zdroj: | American Journal of Hematology. 43:86-90 |
| ISSN: | 1096-8652 0361-8609 |
| DOI: | 10.1002/ajh.2830430203 |
| Popis: | We observed increased hemoglobin A2 (HbA2) levels in an asymptomatic human immunodeficiency virus-1 (HIV1) patient with no previous history of beta-thalassemia. He was treated only with zidovudine (AZT). In an attempt to understand this observation, a retrospective study was initiated to determine whether mean HbA2 levels are higher in AZT-treated patients than in subjects not receiving this drug and to assess if other hematologic alterations are associated with elevated HbA2. One hundred fifty-one HIV-positive cases were investigated; AZT was administered to 81 of them. The mean value of HbA2 was 0.032 (SD +/- 0.005) for the treated group vs. 0.027 (SD +/- 0.004) for the controls. This difference was highly significant (P < 0.001). Twenty-four patients (31%) in the treated group had elevated HbA2 levels vs. none in the controls. Bone marrow toxicity seemed to be more significant in patients with heightened HbA2 values, and HbA2 levels did not increase with CDC clinical stage. We conclude that AZT may be linked to high HbA2 levels in some patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text